Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study of almost 150,000 men from 8 European countries, presented at this year’s European Obesity Summit (Gothenburg, 1-4 June) shows that higher body mass index (BMI) and waist circumference are associated with an increased risk of aggressive prostate cancer.

© kwanchai.c - Shutterstock

Image courtesy of Shutterstock

This analysis of the European Prospective Investigation into Cancer and Nutrition (EPIC) is by Dr Aurora Pérez-Cornago, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK, and colleagues.

To date, evidence on the association of body size and adiposity with prostate cancer risk is not clear. In this study, the authors investigated the associations between various body measurements at baseline, mainly BMI and waist circumference, and the risk of prostate cancer incidence, with a focus on tumour stage and grade, and on mortality from prostate cancer. A total of 141,896 men in 8 European countries (Italy, Spain, United Kingdom, the Netherlands, Greece, Germany, Sweden, and Denmark) from the EPIC cohort were included. Data were adjusted for education level, smoking, marital status, diabetes and physical activity.

Read more (Nuffield Department of Population Health)

Similar stories

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.